Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety Study of Elismetrep in Acute Migraine
NCT07674654Phase 3Recruiting
- Sponsor
- TriGemX Bio
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elismetrep in migraine (2 arms), sponsored by TriGemX Bio. Primary endpoints: Proportion of participants with at least one treatment-emergent adverse event at 1 year, Proportion of participants with at least one treatment-emergent serious adverse event at 1 year and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
elismetrep
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07674654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674654.